Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670751 | 1.00 | S1PR1 (0.80) | S1PR1S1PR3 | |
| SCHEMBL2670846 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3 | |
| Cenerimod SCHEMBL29439050 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL2670878 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3 | |
| Cenerimod SCHEMBL29449748 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL2670844 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3 | |
| Cenerimod SCHEMBL2670991 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3 | |
| Cenerimod SCHEMBL2671193 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3 | |
| Cenerimod SCHEMBL2670989 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL11301223 | 0.89 | S1PR1 (0.77) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133669-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-05-14 | — | — | US | claimed |
| EP-2852575-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | Actelion Pharmaceuticals Ltd. (CH) | 2015-04-01 | — | — | EP | claimed |
| US-8658675-B2 | Pyridin-4-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-25 | — | — | US | claimed |
| WO-2013175397-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-28 | — | — | WO | claimed |
| EP-2454255-B1 | PYRIDIN-4-YL DERIVATIVES AS S1P1/EDG1 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | claimed |
| EP-2454255-A1 | PYRIDIN-4-YL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2012-05-23 | — | — | EP | claimed |
| US-20120108638-A1 | PYRIDIN-4-YL DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2012-05-03 | — | — | US | claimed |
| WO-2011007324-A1 | PYRIDIN-4-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-20 | — | — | WO | claimed |
| US-20150133669-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-05-14 | — | — | US | disclosed |
| EP-2852575-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | Actelion Pharmaceuticals Ltd. (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-8658675-B2 | Pyridin-4-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-25 | — | — | US | disclosed |
| WO-2013175397-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-28 | — | — | WO | disclosed |
| EP-2454255-B1 | PYRIDIN-4-YL DERIVATIVES AS S1P1/EDG1 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | disclosed |
| EP-2454255-A1 | PYRIDIN-4-YL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2012-05-23 | — | — | EP | disclosed |
| US-20120108638-A1 | PYRIDIN-4-YL DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2012-05-03 | — | — | US | disclosed |
| WO-2011007324-A1 | PYRIDIN-4-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108638-A1 | PYRIDIN-4-YL DERIVATIVES | CD4, IL4, FCGRT | S1PR1 121/4885S1PR3 116/4885 |
| US-20150133669-A1 | NEW PROCESS FOR THE PREPARATION OF 2-CYCLOPENTYL-6-METHOXY-ISONICOTINIC ACID | IMPDH1, IMPDH2, ITPA | S1PR1 2195/4885S1PR3 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.